Your Messages Inbox
Your Article Summary
See Latest ArticlesAbbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD, an Investigational Treatment for Mixed Dyslipidemia
Abbott, 06/05/09
Abbott and AstraZeneca announced today that the companies have submitted a New Drug Application to the U.S. Food and Drug Administration for an investigational compound for the treatment of mixed dyslipidemia, a combination of two or more lipid abnormalities including high LDL- cholesterol, high triglycerides and low HDL-cholesterol. The NDA submission for this investigational compound, containing the active ingredients of CRESTOR and TRILIPIX, is supported by data from multiple studies, including efficacy and safety studies with the 5mg, 10mg and 20mg doses of rosuvastatin combined with fenofibric acid.
Today in Regulatory Issues...keeping you current
Receive free subspecialty "5-minute updates" via email
The Unintended Consequences of Clinical Trials Regulations
PLoS Medicine, 12/04/09
Mandatory Disclosure of Pharmaceutical Industry-Funded Events for Health Professionals
PLoS Medicine, 12/02/09
FDA drug approval intervals from 1997 to 2006: analysis and comparison during information technology implementation
International Journal of Electronic Healthcare , 12/01/09
Article Search
Sponsor